Latest Breaking News On - Post hoc analysis from the phase 3 javelin bladder 100 trial - Page 1 : vimarsana.com

A long-term post-hoc analysis from the JAVELIN Bladder 100 trial demonstrated that first-line maintenance avelumab elicited similar overall survival and progression-free survival benefits vs best supportive care alone in patients with advanced urothelial carcinoma.

Srikala sridharDepartment of medicineUniversity of torontoCancers symposiumCancer clinical research unitPrincess margaret cancer centerGenitourinary medical oncologistsMedical advisory boardBladder cancer canadaNew england journalPost hoc analysis from the phase 3 javelin bladder 100 trialFirst line maintenance avelumabPatients with advanced urothelial carcinomaThe university of toronto